INTERCEPT: Identifying and Managing Cancer Treatment Cardiotoxicities in Patients Undergoing Therapy: Cardiovascular Risk for the Cancer Journey
A curriculum designed to engage clinicians in an educational initiative aimed at improving the overall care for cancer patients at risk for cardiotoxicity associated with their treatment. This program is part 2 of 4 live webinars provided by expert clinical faculty.
Apply evidence-based approaches to identify and assess patients at risk for cardiotoxicity.
Discuss the use of clinical tools, imaging, and other tests to evaluate patients at risk for cardiotoxicity before, during, and after cancer treatment.
Employ multidisciplinary strategies to mitigate the risk for cardiotoxicity in cancer patients.
- 1.00 ABIM MOC
- 1.00 ACPE - Pharmacist
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ANCC
- 1.00 Attendance
- 1.00 JA Credit - AH
- 1.00 Approved for AMA PRA Category 1 Credit(s)™
- 1.00 MOC Part 2